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A B S T R A C T
Background: Harm reduction is an evidence-based, effective response to HIV transmission and other
harms faced by people who inject drugs, and is explicitly supported by the Global Fund to Fight AIDS,
Tuberculosis and Malaria. In spite of this, people who inject drugs continue to have poor and inequitable
access to these services and face widespread stigma and discrimination. In 2013, the Global Fund
launched a new funding model-signalling the end of the previous rounds-based model that had operated
since its founding in 2002. This study updates previous analyses to assess Global Fund investments in
harm reduction interventions for the duration of the rounds-based model, from 2002 to 2014.
Methods: Global Fund HIV and TB/HIV grant documents from 2002 to 2014 were reviewed to identify
grants that contained activities for people who inject drugs. Data were collected from detailed grant
budgets, and relevant budget lines were recorded and analysed to determine the resources allocated to
different interventions that were speciﬁcally targeted at people who inject drugs.
Results: 151 grants for 58 countries, plus one regional proposal, contained activities targeting people
who inject drugs–for a total investment of US$ 620 million. Two-thirds of this budgeted amount was for
interventions in the ‘‘comprehensive package’’ deﬁned by the United Nations. 91% of the identiﬁed
amount was for Eastern Europe and Asia.
Conclusion: This study represents an updated, comprehensive assessment of Global Fund investments in
harm reduction from its founding (2002) until the start of the new funding model (2014). It also
highlights the overall shortfall of harm reduction funding, with the estimated global need being US$
2.3 billion for harm reduction in 2015 alone. Using this baseline, the Global Fund must carefully monitor
its new funding model and ensure that investments in harm reduction are maintained or scaled-up.
There are widespread concerns regarding the withdrawal from middle-income countries where harm
reduction remains essential and unfunded through other sources: for example, 15% of the identiﬁed
investments were for countries which are now ineligible for Global Fund support.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Harm reduction – broadly deﬁned as ‘‘policies, programmes and
practices that aim primarily to reduce the adverse health, social
and economic consequences of the use of legal and illegal
psychoactive drugs without necessarily reducing drug consump-
tion’’ (Harm Reduction International, 2011) – is a proven, effectivee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Box 1. The United Nations ‘‘comprehensive package’’ (WHO,
2012)
1. Needle and syringe programmes
2. Opioid substitution therapy and other drug dependence
treatment
3. HIV testing and counselling
4. Antiretroviral therapy
5. Prevention and treatment of sexually transmitted infections
6. Condom distribution programmes for people who inject
drugs and their sexual partners
7. Targeted information, education and communication for
people who inject drugs and their sexual partners
8. Prevention, vaccination, diagnosis and treatment of viral
hepatitis
9. Prevention, diagnosis and treatment of tuberculosis
J. Bridge et al. / International Journal of Drug Policy 27 (2016) 132–137 133and cost-effective approach for people who use drugs, and
especially for preventing the transmission of HIV, viral hepatitis,
tuberculosis and other harms among people who inject drugs. The
World Health Organization (WHO), the Joint United Nations
Programme on HIV/AIDS (UNAIDS) and the United Nations Ofﬁce
on Drugs and Crime (UNODC) have elaborated and endorsed a
‘‘comprehensive’’ package of nine harm reduction interventions for
people who inject drugs (Box 1) – stating that delivery of the whole
package is key, but that ‘‘countries should prioritise implementing
NSPs [needle and syringe programmes] and evidence-based drug
dependence treatment (speciﬁcally OST [opioid substitution
therapy])’’ (WHO, UNODC, & UNAIDS, 2012).
Other international partners have expanded on this package
deﬁned by the United Nations. For example, the United States
President’s Emergency Plan for AIDS Relief (PEPFAR) adds
community-based outreach to the list (PEPFAR, 2010); the
International HIV/AIDS Alliance has outlined a package of
15 interventions including overdose prevention, advocacy, psy-
chosocial support, and legal support (International HIV/AIDS
Alliance, 2010); and the International Drug Policy Consortium
(IDPC) also includes drug consumption rooms/safer injecting
facilities (IDPC, 2012).
The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global
Fund) is the leading international donor for harm reduction
services (Bridge, Hunter, Atun, & Lazarus, 2012). Founded in 2002,
the Global Fund is a partnership between governments, civil
society, the private sector and affected populations. It raises and
invests nearly US$ 4 billion each year for programmes, and works
in line with three core principles: partnerships, country ownership
and performance-based funding – meaning that local partners
implement programmes based on the speciﬁc priorities in each
country, and the Global Fund provides ﬁnancing on the condition
that veriﬁable results are achieved.
From 2002 until 2013, the Global Fund operated via a ‘rounds-
based model’ whereby proposals from eligible countries or
regional bodies were developed and submitted during designated
funding windows, with guidance from the Global Fund and its
partners. Once submitted, proposals were reviewed by an
independent Technical Review Panel, which then made funding
recommendations to the Global Fund Board. Successful proposals
in each ‘round’ were approved for 2 years (‘‘Phase 1’’), after which a
review of progress, results and impact was conducted before
continued funding was approved for the next three years (‘‘Phase
2’’). Some grants from Round 1 (2002) to Round 5 (2005) were also
invited to apply for a further two three-year periods of funding
known as the ‘‘Rolling Continuation Channel’’ (this mechanism was
discontinued after Round 5).
Since its inception, the Global Fund has encouraged applicants
to include harm reduction interventions in their proposals. A seriesof information notes on harm reduction, released since Round 10
(2010), make it clear that the Global Fund ‘‘supports evidence-
based interventions aimed at ensuring that key populations have
access to HIV prevention, treatment, care and support . . .
[including] the comprehensive package for the prevention,
treatment and care of HIV among people who inject drugs’’
(Global Fund, 2010, 2011a, 2014a). In Round 10, the Global Fund
also created a dedicated funding reserve for HIV proposals that
focused on most-at-risk populations (which, in practice, were
people who inject drugs, men who have sex with men, sex workers
and transgender individuals). A similar mechanism was due to be
rolled out in Round 11 (2011), but in November 2011 the Global
Fund Board took the decision to replace Round 11 with a
‘Transitional Funding Mechanism’. In response to economic
uncertainties at the time, this Mechanism limited proposals to
the continuation (rather than scale-up or introduction) of essential
services that faced disruption due to existing grants ending.
In 2012, data were released from a detailed portfolio analysis
from Round 1 (2002) to Round 9 (2009) – showing that the Global
Fund had invested or approved US$ 430 million for activities that
speciﬁcally targeted people who inject drugs. This total included
120 HIV grants for 55 countries and territories – and represented
around 4% of the total amount approved for HIV grants during this
period (Bridge et al., 2012). A subsequent analysis aimed to include
data from Round 10 (2010), taking the total to US$ 580 million
(Harm Reduction International, 2012).
Despite these substantial resources from the Global Fund, the
global funding for harm reduction remains woefully short of the
actual needs (Harm Reduction International, International Drug
Policy Consortium, International HIV/AIDS Alliance, 2014).
UNODC, WHO, UNAIDS and the World Bank have jointly
estimated that there are 12.7 million people who inject drugs
globally, although the broad range provided (8.9–22.4 million)
underlines the paucity of reliable data (UNODC, 2014). Research
has consistently conﬁrmed that people who inject drugs have
poor and inequitable access to services (Mathers et al., 2010), and
face widespread stigma, discrimination, marginalisation and
abuse (Beyrer, Malinowska-Sempruch, Kamarulzaman, & Strath-
dee, 2010). In 2010, it was estimated that just 8% of people who
inject drugs have access to NSPs worldwide, just 8% of people
who inject opiates have access to OST, and just 4% of eligible
people who inject drugs have access to antiretroviral therapy
(ART) (Mathers et al., 2010). Updated global coverage data is
urgently needed.
In February 2013, the Global Fund announced a new funding
model – moving away from its rounds-based, competitive
approach to ‘‘invest more strategically, achieve greater impact,
and engage implementers and partners more effectively’’ (Global
Fund, 2013). Under this new model, the Global Fund determines
funding allocations for each eligible country based on calculations
of country income and national disease burden. Additional funding
has also been set aside for regional proposals. This article employs
the same methodology from previous analyses of Global Fund
investments in harm reduction (Bridge et al., 2012), thus providing
a complete dataset for the entire duration of the Global Fund’s
rounds-based funding model – from Round 1 (2002) to the
Transitional Funding Mechanism that replaced Round 11 (2011).
Methods
The methodology for this Global Fund portfolio analysis has
been outlined in greater detail elsewhere (Bridge et al., 2012).
Speciﬁcally, this study focused on analysing budget data from
applicable Round 10 (2010) and Transitional Funding Mechanism
(2011) grants, alongside ‘‘Phase 2’s’’ and other grant extensions
from earlier rounds for which the ﬁnal budgets were unavailable
Box 2. Intervention codes used in the analysis.
a. Needle and syringe programmes (including equipment, staff
and facilities)
b. Opioid substitution therapy (including equipment, staff and
facilities)
c. HIV testing and counselling (including equipment, staff and
facilities)*
d. Antiretroviral therapy (including equipment, staff and facili-
ties)*
e. Prevention and treatment of sexually transmitted infection
(including equipment, staff, facilities, specific training)*
f. Condom distribution programmes (including equipment,
staff, facilities, specific training)*
g. Targeted information, education and communication (in-
cluding overdose prevention or management)*
h. Prevention, vaccination, diagnosis and treatment of viral
hepatitis (including equipment, staff, facilities, specific training)*
i. Prevention, diagnosis and treatment of tuberculosis (includ-
ing equipment, staff, facilities, specific training)*
j. Building enabling supportive environments (including stig-
ma reduction, advocacy, sensitisation, etc.)*
k. Monitoring and evaluation, and research*
l. Program management (such as overheads, management
fees, infrastructure costs, etc.)**
m. Psychosocial support, legal aid or similar services*
n. Other
x. Services in, or related to, compulsory drug detention centers
z. Training and capacity building (including study visits)**
*Where specifically targeted at people who inject drugs.
** Where specifically targeted at people who inject drugs, and
when not assigned specifically to one of the activities above.
Table 1
Countries with HIV or TB/HIV grants from the Global Fund that included
interventions for people who inject drugs, 2002–2014.
Asia Eastern Europe Latin America
Bangladesh Albania Argentina
Bhutan Armenia Mexico
Cambodia Azerbaijan Paraguay
China Belarus Middle East & North Africa
India Bosnia & Herzegovina Afghanistan
Indonesia Bulgaria Algeria
Malaysia Croatia Egypt
Maldives Estonia Iran
Mongolia Georgia Jordan
Myanmar Kazakhstan Morocco
Nepal Kosovo Palestine
Pakistan Kyrgyzstan Syria
Philippines Macedonia Tunisia
Sri Lanka Moldova Turkey
Thailand Montenegro Sub-Saharan Africa
Timor-Leste Romania Burundi
Vietnam Russia Cape Verde
Serbia Kenya
Tajikistan Madagascar
Ukraine Mauritius
Uzbekistan Nigeria
Tanzania (Zanzibar)
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projections as in the previous analysis, and providing the most
complete available dataset up to the end of 2014.
Relevant HIV grants were identiﬁed by searching grant proposal
documents (which are publicly available from http://portfolio.
theglobalfund.org) for nine key terms: buprenorphine, harm, IDU
[injecting drug use/user], inject, methadone, needle, substitution,
syringe and user.
For applicable grants, the ﬁnal detailed budgets were retrieved
from internal Global Fund databases and with the support of
Global Fund grant management staff. These Microsoft Excel
documents are the result of extensive review and negotiation
between the Global Fund Secretariat and the applicant, and
therefore provide the most detailed source of ﬁnancial data for a
grant – including all planned expenditures and projected costs.
These budgets are not made publicly available due to the
sensitivity of some of the information that they contain (such as
staff salaries and procurement costs).
The relevant budget documents were examined line-by-line for
activities that targeted people who inject drugs. For activities that
target multiple most-at-risk populations including people who
inject drugs, budget data were apportioned equally between each
group: for example, if US$ 200,000 was budgeted for ‘‘condoms for
sex workers and people who inject drugs’’, then US$ 100,000 was
included in this analysis. Activities targeting the general popula-
tion were excluded, as were program management costs (such as
overheads, management fees, infrastructure costs, etc.) unless they
could be speciﬁcally linked to services for people who inject drugs
or the entire grant targeted people who inject drugs. Relevant
budget lines were recorded and coded according to 16 categories
(Box 2). Where necessary, the nature of activities was clariﬁed
using other available grant documents. Data were collated and
analysed using Microsoft Excel. Budget data in currencies other
than US$ were converted using an online currency converter
(www.xe.com), based on the exchange rate from when the grant
started. Grant documents in languages other than English were
translated by multilingual staff at IDPC.
Across this and the previous analysis, a random sample of
16 grants spanning all the examined funding rounds (and
representing approximately one-sixth of the total harm reduction
investments identiﬁed through this analysis) were cross-checked
between the lead researchers (Jamie Bridge and Benjamin Hunter).
Small discrepancies or variations were identiﬁed for some of these
cross-checked grants (accounting for 1.05% of the budgeted totals),
and amendments made where required following discussion
amongst the research team.
Limitations
The methodology for this study carries certain notable
limitations that have been described in detail elsewhere (Bridge
et al., 2012). These include:
 Only HIV and TB/HIV grants were included, possibly omitting
investments from other grants (such as, for example, tuberculo-
sis grants).
 Budget lines for activities that target multiple most-at-risk
populations were divided equally between each group, yet will
likely not be apportioned so simply in practice. However, with
the available data there was no alternative method to apportion
these investments more accurately.
 Activities targeting the general population and untargeted
programme management costs, although excluded from this
analysis, may feasibly reach people who inject drugs. Again, with
the available data there was no alternative method to apportion
these investments. Activities included in grant proposals and budgets may not
directly translate into actual services delivered on the ground.
 Data were not adjusted for the differing costs of, for example,
needles and syringes, HIV tests and treatment in different
countries.
Results
After the systematic ﬁltering process, 151 grants for 58 coun-
tries were found to incorporate speciﬁc activities for people who
inject drugs – as well as one regional proposal (Table 1).
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Fig. 1. Budgeted Global Fund investments for people who inject drugs, by funding round (US$).
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$620 million for activities targeting people who inject drugs. Fig. 1
shows the distribution of investments across the funding rounds,
with an upward trend between Round 7 (2007) and Round 10
(2010), followed by a sharp downturn when Round 11 (2011) was
cancelled. The budgeted totals (rounded) were US$ 16 million for
Round 1 (2002), US$ 57 million for Round 2 (2003), US$ 49 million
for Round 3 (2003), US$ 31 million for Round 4 (2004), US$
19 million for Round 5 (2005), US$ 89 million for Round 6 (2006),
US$ 35 million for Round 7 (2007), US$ 51 million for Round 8
(2008), and US$ 127 million for Round 9 (2009), US$ 135 million
for Round 10 (2010), and US$ 13 million for the Transitional
Funding Mechanism that replaced Round 11 (2011).
Of the 58 countries, 21 were from Eastern Europe and Central
Asia, 17 were from Asia, 10 were from the Middle East and North
Africa, 7 were from Sub-Saharan Africa, and 3 were from Latin
America and the Caribbean. One regional proposal was for the
Middle East and North Africa Harm Reduction Network
(MENAHRA), and covered Afghanistan, Bahrain, Egypt, Iran, Jordan,
Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Syria andTable 2
Distribution of Global Fund investments for harm reduction, by intervention (US$
millions).
Intervention Total budgeted
investment
Needle and syringe programmes 120.3
Opioid substitution therapy 103.1
HIV testing and counselling 25.0
Antiretroviral therapy 26.2
Prevention and treatment of sexually transmitted infections 12.7
Condom distribution programmes 38.0
Targeted information, education and communication 72.0
Prevention, vaccination, diagnosis and treatment of
viral hepatitis
8.6
Prevention, diagnosis and treatment of tuberculosis 5.0
Building enabling supportive environments 19.2
Monitoring and evaluation, and research 27.5
Programme management 95.7
Psychosocial support, legal aid or similar services 22.8
Training and capacity building 21.7
Drug detention centres 7.7
Other 15.0
Total budgeted 620.4
Note: Figures are rounded. ‘‘Other’’ activities include, for example, nutritional
support, primary care and ﬁrst aid, and the prevention of mother-to-child HIV
transmission.Tunisia (Global Fund, 2015a). Asia and Eastern Europe accounted
for 91% of the identiﬁed investments for people who inject drugs.
Table 2 shows how the investments targeting people who inject
drugs were allocated between key interventions. Two-thirds of the
investments were allocated to the nine interventions that
comprise the United Nations’ ‘‘comprehensive package’’ (Box 1)
– with more than half of this amount going to NSP and OST, in line
with the United Nations guidance to prioritise these two ‘‘drug-
user-speciﬁc’’ interventions (WHO, 2012). A further 15% of the
identiﬁed investments were for programme management and
grant overheads that were targeted at people who inject drugs. The
budget analysis also identiﬁed US$ 7.7 million for interventions
and activities in compulsory drug detention centres in Asia.
Discussion
Although harm reduction data from other international donors
are either unavailable or not directly comparable (Harm Reduction
International, 2014), the Global Fund remains a leading source of
international support for harm reduction programmes. The Global
Fund has invested US$ $620 million in activities targeting people
who inject drugs from 2002 to 2014 – with the vast majority for
grants in Eastern Europe and Asia. The identiﬁed investments come
through 151 grants for 58 countries, as well as one regional harm
reduction proposal (Table 1). The total investment identiﬁed
through this analysis is an average of $56.4 million per funding
round – compared to previous ﬁndings of US$ 47.8 million per
funding round from Round 1 to Round 9 (Bridge et al., 2012), and
US$ 25.7 million per funding round from Round 1 to Round 7 (Atun
& Kazatchkine, 2010).
To put these ﬁgures into perspective, between 2002 and the end
of 2011 (i.e. from Round 1 to Round 10) the Global Fund had
approved US$ 12.4 billion for HIV and TB/HIV grants (Global Fund,
2012a) – followed by an additional US$ 111.7 million under the
Transitional Funding Mechanism (Global Fund, 2012b). The US$
620 million identiﬁed in this analysis therefore represents just
under 5% of the total approved funding. Given that an estimated
US$ 2.3 billion is needed in 2015 to deliver the ‘‘comprehensive
package’’ of harm reduction services at levels that can impact upon
the epidemic (Schwartla¨nder et al., 2011), there clearly remains a
global funding crisis for harm reduction (Harm Reduction
International, 2014).
Of the budgeted US$ 620 million, the majority (66%) was
earmarked for the nine components of the ‘‘comprehensive
package’’ (Box 1) – including US$ 120 million for NSPs, and US$
103 million for OST programmes. This is in line with the United
J. Bridge et al. / International Journal of Drug Policy 27 (2016) 132–137136Nations guidance, as well as the Global Fund’s commitment to
funding proven, cost-effective interventions. Some interventions
within this package were allocated noticeably less funding in this
analysis: the totals for HIV testing and counselling, antiretroviral
therapy and sexually transmitted infections may well be under-
estimated by the methodology employed as these services are
commonly delivered and budgeted at the population level, rather
than targeted at speciﬁc most-at-risk populations. The low total for
tuberculosis prevention, treatment and care likely reﬂects the
decision to focus only on HIV and TB/HIV grants in this analysis.
The low total for hepatitis prevention, treatment and care does
seem to reﬂect experiences on the ground, and reﬂects ongoing
debate and confusion as to the Global Fund’s role in treating and
funding services for co-infections – which has since been clariﬁed
by the Global Fund Board, who have agreed to funding co-
infections and co-morbidities of HIV/AIDS, tuberculosis and
malaria provided that certain criteria are met (Global Fund,
2015b).
Beyond the ‘‘comprehensive package’’, around US$ 210 million
was budgeted for other activities – including critical enablers such
as advocacy and sensitisation to build supportive environments
(US$ 19.2 million), psychosocial and/or legal support for people
who inject drugs (US$ 22.8 million), and training and capacity
building (US$ 15 million). The Global Fund Strategy 2012–2016
includes commitments to ‘‘Encourage and support countries to
increase programming that . . . create an enabling social and policy
environment’’ and ‘‘In the context of HIV, promote uptake of
program areas identiﬁed by UNAIDS as critical enablers’’ (Global
Fund, 2011b). Of the US$ 620 million total investment, 15% was
allocated to programme overheads – which include stafﬁng,
building costs, administration and grant management. This is in
line with previous analyses (Bridge et al., 2012) and may reﬂect
high start-up costs for these interventions in many settings.
The budget lines identiﬁed for activities within compulsory
drug detention centres – such as in Cambodia, China and Vietnam –
predate the Global Fund decision to cease all support for the
operation of these centres. These extrajudicial centres continue to
raise major human rights and public health concerns – they are
associated with forced labour and torture (Human Rights Watch,
2010), they do not prevent – and likely even exacerbate – HIV
transmission, and the United Nations has released a joint
statement calling for their immediate closure (UNAIDS, 2012). In
November 2014, the Global Fund formally committed not to
ﬁnance programmes in these facilities (Global Fund, 2014b).
Looking at the harm reduction investments per funding round
(Fig. 1), Round 10 (2010) continued the upward trajectory from
2007. For this round, the Global Fund created a new ‘‘MARPs
Reserve’’ (which ring-fenced 10% of the available HIV funding for
proposals that focus on most-at-risk populations), and also
released their ﬁrst explicit guidance on harm reduction (Global
Fund, 2010). Our data indicate that these initiatives were
successful: of the 32 approved HIV proposals in Round 10,
15 included some level of activity targeted at people who inject
drugs, and two proposals focused entirely on this population (the
regional MENAHRA grant and the grant for Kazakhstan). This
approach was due to be continued before the cancellation of Round
11 (2011), and should be reconsidered by the Global Fund –
particularly for those countries facing reduced funding or
transitioning away from Global Fund support.
The cancellation of Round 11 (2011) abruptly interrupted the
upward trend in Global Fund investments for harm reduction.
Several large harm reduction proposals were shelved – including
one from the Eurasian Harm Reduction Network (EHRN) – and just
US$ 13 million was invested in harm reduction: a 90% drop
compared to Round 10, despite the Global Fund including services
targeted at people who inject drugs as one of the examples of the‘‘essential’’ services that the Transitional Funding Mechanism
sought to continue (Global Fund, 2011c).
In February 2013, the Global Fund announced their new funding
model based on pre-determined funding allocations that each
eligible country can access over a 3-year period, rather than
competitive funding rounds. Proposals still go to the Technical
Review Panel, but there is also now a period of ‘‘country dialogue’’
between the applicant and the Global Fund Secretariat to develop
their strategies. Crucially, funding allocations are made based on
two main criteria: ability to pay (i.e. the country’s income level as
determined by the World Bank) and national disease burden.
Although the Global Fund’s policy commitment to, and
guidance on, harm reduction remains clear (Global Fund,
2014a), serious concerns have been raised that the new funding
model poses a threat to harm reduction investments (Harm
Reduction International, 2014). According to the latest eligibility
list provided by the Global Fund (Global Fund, 2015c), of the
58 countries listed in Table 1, 11 are currently ineligible for Global
Fund support through the new funding model (Argentina, Bosnia
and Herzegovina, China, Croatia, Estonia, Jordan, Kazakhstan,
Macedonia, Mexico, Montenegro, and Turkey) – accounting for 15%
(US$ 92.2 million) of the US$ $620 million total investment for
harm reduction to date. A further three countries are only eligible
via the ‘‘NGO Rule’’ and on certain conditions (Bulgaria, Romania
and Serbia), while Russia is receiving funding only through a
specially arranged ‘‘grace period’’.
Of the eligible countries, more than half are classiﬁed by the
Global Fund as being in ‘‘Band 4’’ – the category of higher income,
lower burden countries for which Global Fund support is the most
restricted and additional incentive funding is not permitted.
Furthermore, 26 of the eligible countries have been labelled by the
Global Fund as ‘over-allocated’ (8 countries) or ‘signiﬁcantly over-
allocated’ (18 countries) – meaning that they are ‘‘receiving more
than what the disease burden and ability-to-pay calculation would
indicate’’ (Global Fund, 2014c), and can expect further reductions
in Global Fund support over the coming years.
In recent years, harm reduction programmes have faced closure
in the absence of sustainable alternative funding following the
withdrawal of Global Fund support (Harm Reduction International,
2014). In Romania, for example, an ‘‘HIV outbreak among IDUs in
2011 coincided with a signiﬁcant reduction of harm reduction
service provision due to the ending of the international pro-
grammes and funding available from the Global Fund’’ (Botescu,
Abagiu, Mardarescu, & Ursan, 2012). In Serbia, harm reduction
services are under increasing threat (EHRN, 2015). In Ukraine,
Global Fund spending on HIV is predicted to drop by 50% between
2014 and 2015, while the government’s HIV prevention budget has
been cut by 71% – with a similar story emerging from Vietnam
(OSF, 2014).
The widespread concern is that both of the criteria used to
calculate allocations under the new funding model are too blunt.
Using only national disease burden data may not adequately reﬂect
concentrated HIV epidemics among people who inject drugs, or in
speciﬁc regions or cities within a country. Using country income
categorisations from the World Bank overlooks vast wealth
inequalities within countries and assumes that reaching a certain
Gross Domestic Product threshold equates to increased willingness
to invest domestic resources in health services for most-at-risk
populations – which is very rarely the case. Furthermore, the
majority of poor people now live in middle income countries (OSF,
2014; Sumner, 2010), as do the majority of people living with HIV
(OSF, 2014), and the majority of people who inject drugs (Harm
Reduction International, 2014). According to the Global Fund’s
own analyses, ‘‘Upper-Middle Income’’ countries account for 18%
of the disease burden, yet receive just 8% of the new funding model
allocations (Global Fund, 2015d).
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should undertake further analysis as a matter of urgency to
measure and understand the impact of the new funding model on
harm reduction funding as and when concept notes are submitted
and new grant agreements are signed. Such analysis should also
inform the development of the Global Fund’s new strategy for
2017–2021.
In addition to the country allocations, funding has also been set
aside for regional proposals. EHRN was invited to apply as an ‘‘early
applicant’’ as part of the transition to the new funding model, and
subsequent harm reduction proposals have been submitted or
developed in East Africa and Asia. This is a welcome avenue for
greater funding for the critical enablers such as advocacy and
community systems strengthening.
Conclusions
This article presents the most up-to-date and complete picture
of Global Fund ﬁnancing for harm reduction from 2002 until the
roll-out of the new funding model in 2014. It demonstrates that the
Global Fund remains a major donor for services that target people
who inject drugs – with an estimated US$ 620 million budgeted
through 152 grants.
However, there remains a global crisis in harm reduction
funding, which falls far short of the estimated need. Despite the
Global Fund receiving a record level of donor pledges in 2013, the
strategic shift away from funding middle-income countries may
have major implications for harm reduction, especially in Eastern
European and Asian countries which are not politically prepared to
replace Global Fund resources for these programmes with
domestic funding.
The Global Fund’s Key Populations Action Plan 2014–2017
includes a commitment to ‘‘evaluate the impact of the new funding
model in meeting the needs of key populations’’. Using these
updated data as the baseline, the Global Fund must carefully assess
how funding for harm reduction in the new funding model
compares to that in the rounds-based model. A portfolio analysis
using this same methodology should be conducted once a
sufﬁcient number of new funding model grants have been
approved (i.e. early 2016) to mitigate against a downturn in
investments that is foreseen by some stakeholders.
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